NASDAQ:SNOA

Sonoma Pharmaceuticals - SNOA Stock Forecast, Price & News

$1.64

+0.01 (+0.61%)

(As of 02/3/2023 12:00 AM ET)

Add

Compare

Today's Range: $1.58
▼
$1.70
50-Day Range: $1.01
▼
$2.02
52-Week Range: $1.00
▼
$4.25

Volume: 233,758 shs
Average Volume: 5.68 million shs
Market Capitalization: $5.08 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Institutional Ownership

About Sonoma Pharmaceuticals (NASDAQ:SNOA) Stock

Sonoma Pharmaceuticals, Inc. engages in developing and producing Stabilized Hypochlorous acid (HOCl) products for a wide range of applications, including wound care, animal health care, eye care, nasal care, oral care and dermatological conditions. Its products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. The company was founded by Hojabr Alimi and Linda Alimi in April 1999 and is headquartered in Boulder, CO.

Receive SNOA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sonoma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SNOA Stock News Headlines

January 31, 2023 | finance.yahoo.com

Sonoma Pharmaceuticals Announces Partnership with Daewoong Pharmaceutical for Distribution of Primocyn Skin Care in South Korea

January 25, 2023 | marketwatch.com

Sonoma Pharma Shares Rise 82% After Pricing Agreement for Microcyn Rx Products

February 4, 2023 | Investor Place Media (Ad)

Cash Holders STILL Aren't Taking Steps to Prepare

Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.

January 25, 2023 | benzinga.com

These Four Companies Are Attracting Investors Following Recent News

January 25, 2023 | finanznachrichten.de

Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals and EMC Pharma Announce Department of Defense DAPA Registration for Microcyn Rx Products

January 25, 2023 | investorplace.com

Why Is Sonoma Pharmaceuticals (SNOA) Up 70% Today?

January 25, 2023 | finance.yahoo.com

Sonoma Pharmaceuticals and EMC Pharma Announce Department of Defense DAPA Registration for Microcyn(R) Rx Products

January 4, 2023 | finance.yahoo.com

Sonoma Pharmaceuticals Launches Two New Products Expanding Its Line of Office Dispense Products Exclusively for Dermatologists and Medical Spas

February 4, 2023 | Investor Place Media (Ad)

Cash Holders STILL Aren't Taking Steps to Prepare

November 17, 2022 | finance.yahoo.com

Sonoma Pharmaceuticals Second Quarter 2023 Earnings: US$0.33 loss per share (vs US$0.043 loss in 2Q 2022)

November 15, 2022 | finanznachrichten.de

Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Second Quarter 2023 Financial Results

November 15, 2022 | finance.yahoo.com

Sonoma Pharmaceuticals Reports Second Quarter 2023 Financial Results

October 27, 2022 | finanznachrichten.de

Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Launches Two New Dermatological Products for Over-The-Counter Use in the United States

October 27, 2022 | finance.yahoo.com

Sonoma Pharmaceuticals Launches Two New Dermatological Products for Over-The-Counter Use in the United States

October 6, 2022 | finance.yahoo.com

Sonoma Pharmaceuticals to Exhibit at Upcoming CPHI Conference in Frankfurt, Germany

August 13, 2022 | seekingalpha.com

Sonoma Pharmaceuticals GAAP EPS of -$0.29, revenue of $3.99M

August 11, 2022 | finanznachrichten.de

Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports First Quarter 2023 Financial Results

August 11, 2022 | finance.yahoo.com

Sonoma Pharmaceuticals Reports First Quarter 2023 Financial Results

August 2, 2022 | finance.yahoo.com

Sonoma Pharmaceuticals Launches MicrocynVS(R) Line of Products Exclusively for Veterinarian Use and Announces Partnership with DV Medical Supply

July 13, 2022 | finanznachrichten.de

Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2022 Financial Results

July 13, 2022 | finance.yahoo.com

Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2022 Financial Results

June 1, 2022 | seekingalpha.com

Sonoma gains on new U.S. EPA designation for disinfectant

June 1, 2022 | finance.yahoo.com

Sonoma Pharmaceuticals and MicroSafe Group DMCC Announce that U.S. EPA has Added Nanocyn® Hospital-Grade Disinfectant to List N for Use Against COVID-19

May 4, 2022 | seekingalpha.com

Sonoma, XORTX top healthcare gainers; Spero, Semler Scientific lead losers' pack

May 3, 2022 | investorplace.com

Why Is Sonoma Pharmaceuticals (SNOA) Stock Up 30% Today?

May 3, 2022 | uk.investing.com

Here's How PayPal Helped Trigger EU Antitrust Allegations Against Apple

May 3, 2022 | morningstar.com

Thinking about buying stock in Sonoma Pharmaceuticals, Chegg, SOS, Redbox Entertainment, or Better Therapeutics?

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive SNOA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sonoma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SNOA Company Calendar

Last Earnings: 11/14/2022
Today: 2/04/2023
Next Earnings (Estimated): 2/10/2023
Fiscal Year End: 3/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SNOA
CUSIP: N/A
CIK: 1367083
Web: www.sonomapharma.com
Phone: (800) 759-9305
Fax: 707-283-0551
Employees: 14
Year Founded: 1999

Profitability

EPS (Most Recent Fiscal Year): ($1.88)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-5,090,000.00
Net Margins: -46.28%
Pretax Margin: -48.46%
Return on Equity: -61.54%
Return on Assets: -30.50%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.51
Quick Ratio: 2.66

Sales & Book Value

Annual Sales: $12.63 million
Price / Sales: 0.40
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.81 per share
Price / Book: 0.58

Miscellaneous

Outstanding Shares: 3,100,000
Free Float: 2,810,000
Market Cap: $5.08 million
Optionable: Not Optionable
Beta: 1.19

Social Links

Key Executives

Amy M. Trombly
Chief Executive Officer & Director

Bruce Thornton
Chief Operating Officer & Secretary

Chad White
Chief Financial Officer

Key Competitors

View All Competitors

Insiders & Institutions

Citadel Advisors LLC
Sold 7,308 shares on 11/15/2022
Ownership: 0.593%

View All Institutional Transactions

SNOA Stock - Frequently Asked Questions

How have SNOA shares performed in 2023?: Sonoma Pharmaceuticals' stock was trading at $1.12 on January 1st, 2023. Since then, SNOA stock has increased by 46.4% and is now trading at $1.64.
View the best growth stocks for 2023 here.
When is Sonoma Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, February 10th 2023.
View our SNOA earnings forecast.
How were Sonoma Pharmaceuticals' earnings last quarter?: Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) released its quarterly earnings results on Monday, November, 14th. The company reported ($0.19) EPS for the quarter. The business earned $3.33 million during the quarter. Sonoma Pharmaceuticals had a negative net margin of 46.28% and a negative trailing twelve-month return on equity of 61.54%.
What other stocks do shareholders of Sonoma Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Sonoma Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), VelocityShares Daily 2x VIX Short-Term ETN (TVIX), Sorrento Therapeutics (SRNE), Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Amarin (AMRN), Pfizer (PFE), Nabriva Therapeutics (NBRV), Verastem (VSTM) and Vaxart (VXRT).

What is Sonoma Pharmaceuticals' stock symbol?: Sonoma Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNOA."
How do I buy shares of Sonoma Pharmaceuticals?: Shares of SNOA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Sonoma Pharmaceuticals' stock price today?: One share of SNOA stock can currently be purchased for approximately $1.64.
How much money does Sonoma Pharmaceuticals make?: Sonoma Pharmaceuticals (NASDAQ:SNOA) has a market capitalization of $5.08 million and generates $12.63 million in revenue each year. The company earns $-5,090,000.00 in net income (profit) each year or ($1.88) on an earnings per share basis.
How can I contact Sonoma Pharmaceuticals?: Sonoma Pharmaceuticals' mailing address is 645 MOLLY LANE SUITE 150, WOODSTOCK GA, 30189. The official website for the company is www.sonomapharma.com. The company can be reached via phone at (800) 759-9305, via email at dmcfadden@sonomais.com, or via fax at 707-283-0551.

This page (NASDAQ:SNOA) was last updated on 2/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial